ResMed (ASX:RMD) reported Thursday fiscal third-quarter earnings of $2.37 per diluted share on a non-GAAP basis, up from $2.13 per diluted share a year earlier.
On a GAAP basis, diluted earnings per share rose to $2.58 from $2.04 year on year, the filing said.
Analysts polled by Visible Alpha were expecting EPS of $2.22.
Revenue for the three months ended March 31 was $1.29 billion, up 8% from $1.19 billion in the same period last year. Analysts surveyed by Visible Alpha expected $1.27 billion.
The board declared a quarterly dividend of $0.053 per share, up from the $0.048 in the previous reported period, payable on June 12 to shareholders on record as of May 8.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.